Abstracts tagged "Systemic lupus erythematosus (SLE)"

Abstract Number: 1675 • ACR Convergence 2020
Microstructural Damage Is Associated with Age at Disease-onset and Cognitive Impairment in Systemic Lupus Erythematosus
Paulo Julio¹, Renan Frittoli¹, Aline Lapa¹, Thais Caldeira¹, Leticia Rittner¹, Fernando Cendes¹, Roberto Marini¹, Paula Fernandes¹, Lilian Costallat¹ and Simone Appenzeller¹, ¹UNICAMP, Campinas, Brazil
Background/Purpose: To compare corpus callosum (CC) volume and diffusion tensor imaging in systemic lupus erythematosus according to age of disease-onset. Methods: We selected 75 patients with…
Abstract Number: 1785 • ACR Convergence 2020
Use of Contraceptive Methods in Mexican Women with Rheumatic Diseases
Jazzia Emily Diaz-Angulo¹, Cassandra M. Skinner-Taylor¹, Lorena Perez-Barbosa¹, Eugenio Salvador Barriga-Maldonado¹, Marco Valdovinos², Rita Pineda-Sic¹, Jesus Alberto Cardenas-de la Garza¹, Gabriel Figueroa-Parra³, Janett Carmen Riega-Torres⁴ and Dionicio Ángel Galarza-Delgado⁵, ¹Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México., Monterrey, Nuevo Leon, Mexico, ²Hospital Universitario José Eleuterio González, Monterrey, Nuevo Leon, Mexico, ³Universidad Autonoma de Nuevo Leon, Monterrey, Mexico, ⁴Rheumatology Service, University Hospital “Dr. José Eleuterio González”, Universidad Autónoma de Nuevo León, Monterrey, México., Monterrey NL, Nuevo Leon, Mexico, ⁵Rheumatology Service, Hospital Universitario “Dr. José Eleuterio González”, Universidad Autónoma Nuevo León, Monterrey, Nuevo Leon, Mexico
Background/Purpose: The importance of safe and effective contraception for women with rheumatic diseases has been increasing. Several studies have demonstrated that carefully planned pregnancies are…
Abstract Number: 1805 • ACR Convergence 2020
Longitudinal Analysis of IFN Status and Disease Characteristics in SLE
Melissa Northcott¹, Alberta Hoi², Rachel Koelmeyer³ and Eric Morand⁴, ¹Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Victoria, Australia, ²Monash University, Melbourne, Victoria, Australia, ³Monash University, Clayton, Victoria, Australia, ⁴Medicine, School of Clinical Sciences at Monash Health, Monash University, Melbourne, Australia
Background/Purpose: The type 1 interferon (IFN) cytokine family is key to the pathogenesis of SLE, evidenced by the expression of IFN stimulated genes (ISGs) in…
Abstract Number: 1822 • ACR Convergence 2020
Serum Proteomics from a Phase III, Randomized, Placebo-Controlled Study of Patients with Active Lupus Nephritis: Correlation with Baseline Disease Characteristics and Response to Therapy
Shiliang Wang¹, Richard Furie², Mary Anne Dooley³, David Wofsy⁴, Tsutomu Takeuchi⁵, Ana Malvar⁶, Andrea Doria⁷, Juanita Romero-Díaz⁸, Tak Mao Chan⁹, Gerald Appel¹⁰, David Jayne¹¹, Sarah Hu¹², Sheng Gao¹³ and Michael Maldonado¹², ¹Bristol-Myers Squibb Company (at the time of analysis), Princeton, NJ, ²Zucker School of Medicine at Hofstra/Northwell, Great Neck, NY, ³University of North Carolina, Chapel Hill, NC, ⁴University of California San Francisco, San Francisco, CA, ⁵Division of Rheumatology, Department of internal Medicine, School of Medicine, Keio University, Tokyo, Japan, ⁶Organizacion Medica de Investigacion, Buenos Aires, Argentina, ⁷University of Padua, Padua, Italy, ⁸Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran, Mexico City, Mexico, ⁹University of Hong Kong, Hong Kong, Hong Kong, ¹⁰Columbia University Medical Center, New York, NY, ¹¹Department of Medicine, Vasculitis and Lupus Research Group, University of Cambridge, Cambridge, UK, Cambridge, United Kingdom, ¹²Bristol-Myers Squibb Company, Princeton, NJ, ¹³Bristol-Myers Squibb Company (at the time of analysis), Princeton, NY
Background/Purpose: The ALLURE study compared efficacy and safety of abatacept (ABA) vs placebo (PBO) on background MMF and CS for the treatment of active proliferative…
Abstract Number: 1839 • ACR Convergence 2020
Medication Adherence Barriers and Opportunities to Overcome Them Among Patients with SLE
Lena Eder¹, Megan Clowse², Amanda Eudy³, Jennifer Rogers⁴, Rebecca Sadun³, Lisa Criscione-Schreiber⁵, Jayanth Doss³, Mithu Maheswaranathan⁶, Amy Corneli⁷, Hayden Bosworth⁶ and Kai Sun⁶, ¹Duke University Hospital, Chapel Hill, NC, ²Duke University, Chapel Hill, NC, ³Duke University, Durham, NC, ⁴Duke University Hospital, Durham, DE, ⁵Division of Rheumatology and Clinical Immunology, Department of Medicine, Duke University Medical Center, Durham, NC, ⁶Duke University Hospital, Durham, ⁷Duke University, Durham
Background/Purpose: Medication non-adherence in SLE is as high as 80%, yet little is known about adherence barriers faced by patients or interventions that improve adherence…
Abstract Number: PP07 • ACR Convergence 2020
Improving Communication with My Physician Drastically Improved My Health
Whitney Carter¹, ¹Lupus and Allied Diseases Association, Inc., Pleasanton, CA
Background/Purpose: In 2011, at the age of 14, I was sent to the emergency room with a platelet count of 19. The hematologist diagnosed me…
Abstract Number: 0242 • ACR Convergence 2020
Autoantibody Profile and Ethnicity: Risk Factors for Accelerated Development of Lupus Nephritis
Majed Albirdisi¹, David d'Cruz², Shirish Sangle² and Natasha Jordan³, ¹King Fahad Medical City, riyadh, Saudi Arabia, ²guys and st thomas hospital, london, United Kingdom, ³addebrooke's hospital, cambridge, United Kingdom
Background/Purpose: Systemic Lupus Erythematosus (SLE) is a multisystem autoimmune disease. African ancestry is associated with an increased risk of Lupus Nephritis (LN). Anti-DNA autoantibodies play…
Abstract Number: 0258 • ACR Convergence 2020
Using Patient-Reported Outcomes Measures to Classify Patients with Systemic Lupus Erythematous
Amanda Eudy¹, Bryce Reeve², Theresa Coles², Li Lin², Jennifer Rogers³, Lisa Criscione-Schreiber⁴, Jayanth Doss¹, Kai Sun¹, Rebecca Sadun¹, Patricia Katz⁵, David Pisetsky⁶ and Megan Clowse⁷, ¹Duke University, Durham, NC, ²Duke University, Durham, ³Duke, Durham, NC, ⁴Duke University School of Medicine, Durham, NC, ⁵University of California, San Francisco, Novato, CA, ⁶Duke University Medical Center, Durham, NC, ⁷Duke University, Chapel Hill, NC
Background/Purpose: Because systemic lupus erythematosus (SLE) is a complex and heterogeneous disease, we have developed a conceptual model that divides SLE activity into two dimensions:…
Abstract Number: 0275 • ACR Convergence 2020
Paradoxical Relationship Between Disease Activity and Satisfaction with Care in Lupus
Sana Afroz¹, Ailda Nika², Winston Sequeira³, Joel Block⁴, Patricia Katz⁵ and Meenakshi Jolly², ¹RUMC, chicago, IL, ²Rush University, Chicago, IL, ³Rush University Medical Center, Oak Brook, IL, ⁴Rush University Medical Center, Chicago, ⁵University of California, San Francisco, Novato, CA
Background/Purpose: Satisfaction with care (SC) is increasingly being used as a surrogate of QOC, with growing emphasis on optimizing SC/patient experience in health care. We…
Abstract Number: 0293 • ACR Convergence 2020
Contraction of the Stool Taxa Clostridia Is Associated with the Development of Clinical Disease Among Anti-Ro+ Mothers of Children with Neonatal Lupus
Robert Clancy¹, Miranda Marion², Peter Izmirly³, Mala Masson⁴, Hannah Ainsworth², Timothy Howard⁵, Jill Buyon⁶ and Carl Langefeld⁷, ¹NYU School of Medicine, New York, ²Wake Forest School of Medicine, Winston-Salem, ³Department of Medicine, New York University School of Medicine, New York, NY, ⁴New York University School of Medicine, New York, ⁵Wake Forest School of Medicine, Winston-Salem, NC, ⁶Department of Medicine, NYU School of Medicine, New York, NY, ⁷Wake Forest School of Medicine, Winston Salem, NC
Background/Purpose: Anti-Ro autoantibody production often precedes the development of systemic lupus erythematosus (SLE) or Sjögren’s syndrome (SS) by years. Anti-Ro+ mothers of children with manifestations…
Abstract Number: 0437 • ACR Convergence 2020
Integrating Reproductive Health in Systemic Lupus Erythematosus in a Tertiary Care Setting
Jun Chu¹, Sarthak Gupta¹, Zerai Manna², Michael Davis¹, Yenealem Temesgen-Oyelakin¹, Elaine Poncio¹, Isabel Ochoa¹, Laura Lewandowski³, Mariana Kaplan⁴, Alan Decherney¹ and Sarfaraz Hasni², ¹National Institutes of Health, Bethesda, MD, ²Lupus Clinical Trials Unit, NIAMS/NIH, Bethesda, MD, ³NIAMS, NIH, Rockville, MD, ⁴National Institute of Arthritis and Musculoskeletal and Skin Diseases, Bethesda, MD
Background/Purpose: Systemic Lupus Erythematosus (SLE) predominantly affects women of childbearing age. Women affected by SLE have higher risk for infertility, miscarriages, and other pregnancy complications…
Abstract Number: 0575 • ACR Convergence 2020
The Impact of an Integrated Care Management Program on Acute Care Utilization and Outpatient Appointment Attendance Among High-Risk Patients with Lupus
Jessica Williams¹, Weixing Huang², Jamie Collins³, Kreager Taber¹, Katherine McLaughlin¹, Rebecca Cunningham¹, Christine Vogeli⁴, Lisa Wichmann¹ and Candace Feldman³, ¹Brigham and Women's Hospital, Boston, MA, ²Division of Rheumatology, Inflammation, and Immunity; Brigham and Women’s Hospital and Harvard Medical School, Boston, ³Brigham and Women's Hospital, Boston, ⁴Massachusetts General Hospital, Boston, MA
Background/Purpose: Patients with systemic lupus erythematosus (SLE) are often members of disadvantaged groups and some struggle with high acute care utilization and missed outpatient appointments.…
Abstract Number: 0841 • ACR Convergence 2020
CD6 Modulation Ameliorates Kidney and Skin Disease in a Spontaneous Murine Lupus Model
Samantha Chalmers¹, Sayra Garcia¹, Rajalakshmy Ayilam Ramachandran², Chandra Mohan², Leal Herlitz³, Dalena Chu⁴, Jeanette Ampudia⁴, Cherie Ng⁵, Stephen Connelly⁴ and Chaim Putterman¹, ¹Albert Einstein College of Medicine, Bronx, NY, ²University of Houston, Houston, TX, ³Cleveland Clinic, Cleveland, OH, ⁴Equillium, Inc, San Diego, CA, ⁵Equillium, Inc, La Jolla, CA
Background/Purpose: T cells are an important contributor to the pathogenesis of SLE and lupus nephritis, and thus present themselves as interesting therapeutic targets. CD6 is…
Abstract Number: 0860 • ACR Convergence 2020
PREVAIL 1: A Multiple Ascending Dose Study in Normal Healthy Volunteers of PRV-3279, a Novel Bispecific DART Molecule Targeting CD32B and CD79B on B Cells, with Potential for Treatment of SLE
Paul Dunford¹, Gail Comer¹, Ralph Raymond¹, Donald Jung¹, Paul Moore², Francisco Leon¹ and Joan Merrill³, ¹Provention Bio, Oldwick, NJ, ²MacroGenics, Rockville, MD, ³Oklahoma Medical Research Foundation, Oklahoma City, OK
Background/Purpose: B-cell targeted therapeutics have proven efficacious in the treatment of autoimmune disorders. A desired improvement in efficacy and safety necessitate the development of alternate,…
Abstract Number: 0948 • ACR Convergence 2020
Mass Cytometry Reveals Activation Heterogeneity of Circulating Neutrophils in Systemic Lupus Erythematosus
Ricardo Grieshaber-Bouyer¹, Joshua Keegan², Peter Nigrovic³, James Lederer⁴ and Deepak Rao², ¹Department of Medicine V, Hematology, Oncology and Rheumatology, Heidelberg University Hospital, Heidelberg, Germany; Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA, Heidelberg, Germany, ²Brigham and Women's Hospital, Boston, MA, ³Division of Rheumatology, Inflammation and Immunity, Brigham and Women's Hospital, Harvard Medical School, Boston, MA, USA; Division of Immunology, Boston Children's Hospital, Harvard Medical School, Boston, MA, USA, Boston, ⁴BWH Harvard Medical School, Boston, MA
Background/Purpose: Neutrophils are important effector cells in systemic immune-mediated diseases. Neutrophil phenotypes vary depending on their age, maturity, activation state, and local environment; however, differences…

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM CT on October 25. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].